UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 1, 2008
AIDA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
Nevada
(State or other jurisdiction of incorporation)
|
000-50212
(Commission
File Number)
|
81-0592184
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
31 Dingjiang Road, Jianggan District
Hangzhou, China
(Address of principal executive offices)
|
310016
(Zip Code)
|
Registrant’s telephone number, including area code:
86-0571-85802712
Copies to:
Richard Friedman, Esq.
Benjamin Tan, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32 Floor
New York, New York 10006
Phone: (212) 930-9700
Fax: (212) 930-9725
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
□
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 9.01
Financials Statements and Exhibits
(d)
Exhibit No.
Exhibit Description
99.1
Press Release dated April 1, 2008
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AIDA PHARMACEUTICALS, INC.
Dated: April 1, 2008
By:
/s/ Biao Jin
Name: Biao Jin
Title: Chief Executive Officer